BCMA-GPRC5D CAR-T Cells Therapy (Bio-Gene)

N/A

Report date: 2024/12/20 15:33:42

Base Information

Drug NameBCMA-GPRC5D CAR-T Cells Therapy (Bio-Gene)
Drug Alias NameBispecific BCMA-GPRC5D Chimeric antigen receptor (CAR) T-cells Therapy (Bio-Gene)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Dual-target CAR-T cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-BCMAAnti-GPRC5DT lymphocyte replacements
TargetsB-cell maturation proteinG-protein coupled receptor family C group 5member D
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGuangzhou Bio-Gene Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGuangzhou Bio-Gene Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A